Performance status, adverse features and other diseases
Hi all members with increases blast cells/AML,
Now National Comprehensive Cancer Network has decided about recommendations for induction chemotherapy for patients with AML and consider age 60 as a therapeutic divergence point. For older patients (>60 years) with AML, the updated guidelines recommend that patient performance status, in addition to adverse features and comorbid conditions need to be considered when selecting treatment in addition to a patient’s chronological age alone. http://www.checkorphan.org/news/upda...ment_selection Kind regards Birgitta-A |
All times are GMT -4. The time now is 07:49 PM. |
Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright © 2006-2020 Marrowforums.org